Literature DB >> 2137960

Stratifying the patient at risk from coronary disease: new insights from the Framingham Heart Study.

D Levy1, P W Wilson, K M Anderson, W P Castelli.   

Abstract

Although cardiovascular disease remains the leading cause of death in the United States, cardiovascular disease mortality has decreased steadily during the past 2 decades. This trend is largely attributable to improved detection and management of cardiovascular risk factors, in which the Framingham Heart Study has played a major role. This article examines some of the risk factors associated with coronary heart disease, notably, advancing age, hypertension, left ventricular hypertrophy, smoking, elevated serum cholesterol, and reduced high-density lipoprotein, all of which have been investigated by the Framingham Heart Study. In addition, new data are presented from a multidimensional model of coronary heart disease. This is a novel approach that takes into account the interactions of multiple risk factors and their contribution to overall coronary heart disease risk.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2137960     DOI: 10.1016/s0002-8703(05)80050-x

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  31 in total

1.  Plasma lipids and lipoproteins and the prevalence of risk for coronary heart disease in Canadian adults. Canadian Heart Health Surveys Research Group.

Authors:  P W Connelly; D R MacLean; L Horlick; B O'Connor; A Petrasovits; J A Little
Journal:  CMAJ       Date:  1992-06-01       Impact factor: 8.262

2.  Prevalence, control and awareness of high blood pressure among Canadian adults. Canadian Heart Health Surveys Research Group.

Authors:  M R Joffres; P Hamet; S W Rabkin; D Gelskey; K Hogan; G Fodor
Journal:  CMAJ       Date:  1992-06-01       Impact factor: 8.262

3.  Multiple cardiovascular disease risk factors in Canadian adults. Canadian Heart Health Surveys Research Group.

Authors:  S MacDonald; M R Joffres; S Stachenko; L Horlick; G Fodor
Journal:  CMAJ       Date:  1992-06-01       Impact factor: 8.262

4.  Impact of hypertension on short- and long-term prognoses in patients with ST elevation myocardial infarction and without previously known diabetes.

Authors:  Chiara Lazzeri; Serafina Valente; Marco Chiostri; Paola Attanà; Claudio Picariello; Gian Franco Gensini
Journal:  Heart Vessels       Date:  2011-07-07       Impact factor: 2.037

5.  Metabolic profile of indapamide sustained-release in patients with hypertension: data from three randomised double-blind studies.

Authors:  P Weidmann
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

6.  Relationship between regional 18F-fluorodeoxyglucose and 13N ammonia uptake in normal myocardium assessed by positron emission tomography: patterns of mismatch and effects of aging.

Authors:  K F Kofoed; J D Hove; J Freiberg; U Høst; B Hesse; H Kelbaek
Journal:  Int J Cardiovasc Imaging       Date:  2001-10       Impact factor: 2.357

7.  Impact of hypertension history on short and long-term prognosis in patients with acute myocardial infarction treated with percutaneous angioplasty: comparison between STEMI and NSTEMI.

Authors:  Emanuele Cecchi; Maria Grazia D'Alfonso; Marco Chiostri; Elena Parigi; Daniele Landi; Serafina Valente; Salvatore Mario Romano; Gian Franco Gensini; Cristina Giglioli
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-11-12

8.  Defensive hostility, gender and cardiovascular levels and responses to stress.

Authors:  K F Helmers; D S Krantz
Journal:  Ann Behav Med       Date:  1996

9.  Does consideration of either psychological or material disadvantage improve coronary risk prediction? Prospective observational study of Scottish men.

Authors:  John Macleod; Chris Metcalfe; George Davey Smith; Carole Hart
Journal:  J Epidemiol Community Health       Date:  2007-09       Impact factor: 3.710

10.  The efficacy and tolerability of amlodipine and hydrochlorothiazide in Nigerians with essential hypertension.

Authors:  A A Ajayi; A O Akintomide
Journal:  J Natl Med Assoc       Date:  1995-07       Impact factor: 1.798

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.